Overview
Tesamorelin and sermorelin are both synthetic analogues of growth hormone-releasing hormone (GHRH). They differ in length, in the populations studied and in the kind of evidence published. No source checked compares them head to head, so this page sets the two published records side by side. It describes clinical research on licensed medicines. Stackpure products are laboratory research reagents and are not for human use.
Side by side
| Point | Detail | Source |
|---|---|---|
| Structure | Sermorelin is a 29 amino acid GHRH analogue, the shortest synthetic peptide with full GHRH activity. Tesamorelin is described in its trials as GHRH(1-44). | Prakash 1999, Falutz 2010 |
| Main published use | Sermorelin: diagnosis and treatment of children with idiopathic growth hormone deficiency. Tesamorelin: reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. | Prakash 1999, Grunfeld 2011 |
| Dosing used in the studies | Sermorelin: 1 microg/kg intravenously as a diagnostic test; 30 microg/kg subcutaneously at bedtime in treatment studies. Tesamorelin: 2 mg subcutaneously daily in the Phase 3 trials. | Prakash 1999, Falutz 2010 |
| Key result | Sermorelin: height velocity gains sustained over 12 months in some children. Tesamorelin: visceral fat fell 24 cm2 versus a rise of 2 cm2 with placebo, and IGF-I rose 108 ng/mL. | Prakash 1999, Falutz 2010 |
| Trial size | Sermorelin: 18 children in an early trial. Tesamorelin: 806 patients in the pooled Phase 3 analysis. | Ross 1987, Falutz 2010 |
| Antibodies | Sermorelin: anti-GHRH antibodies in 14 of 18 children, with no apparent effect on growth. Tesamorelin: not summarised in the sources checked here. | Ross 1987 |
What each record covers
For sermorelin, the review reports that an intravenous 1 microg/kg test gave a rapid, relatively specific GH response with fewer false positives than other provocative tests, and that once-daily subcutaneous treatment raised height velocity in some prepubertal children (Prakash 1999). For tesamorelin, two multicentre, double-blind, placebo-controlled Phase 3 trials in HIV-infected patients with excess abdominal fat reported lower visceral adipose tissue, with the change largely lost when treatment stopped (Falutz 2010). See the sermorelin overview and the tesamorelin overview for each compound in full.
What the sources do not show
- No head-to-head study of tesamorelin and sermorelin appears in the sources checked.
- The two compounds were studied in different populations (children with growth hormone deficiency versus adults with HIV lipodystrophy), so their results should not be compared directly.
- No source checked reports a half-life comparison, so none is given.
- No source checked compares either with CJC-1295. For CJC-1295 see the DAC vs No DAC comparison.
Related research products and tools
- Tesamorelin peptide vial
- Sermorelin peptide vial
- Tesamorelin calculator
- Sermorelin calculator
- CJC-1295 DAC vs No DAC
Frequently Asked Questions
What is the difference between tesamorelin and sermorelin?
Both are GHRH analogues. Sermorelin is 29 amino acids and was studied in children with growth hormone deficiency. Tesamorelin is described as GHRH(1-44) and was studied in adults with HIV lipodystrophy (Prakash 1999, Falutz 2010).
Has tesamorelin been compared with sermorelin?
Not head to head in the sources checked.
How does tesamorelin compare with CJC-1295?
The sources checked do not compare them. See the CJC-1295 research pages for that compound.
Key References
- Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999. PubMed 18031173
- Ross RJ, et al. Treatment of growth-hormone deficiency with growth-hormone-releasing hormone. Lancet. 1987. PubMed 2879138
- Falutz J, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab. 2010. PubMed 20554713
- Grunfeld C, et al. Tesamorelin. Nat Rev Drug Discov. 2011. PubMed 21283099
For research use only. Not for human consumption.